Abstract
The aim of the research study was to formulate a novel, biodegradable, injectable in situ gel system of Methotrexate (MTX) in the management of Rheumatoid Arthritis (RA). Varying concentration of Pluronic F-127 (20% and 22% w/v) and xanthan gum (0.2%-0.6% w/v) were used in the development of the formulations. In vitro and in vivo studies were carried out for the prepared MTX in situ gels. The results demonstrated that MTX was uniformly distributed and the in situ gels were sterile and syringeable. The gels showed thermosensitivity and thermoresponsivity dependent on concentration and composition of co-polymers. The optimized formulation exhibited drug release of 95.29% at 132 h. Polymer concentration and composition influenced the release of the drug from the prepared in situ gels. Drug release patterns for the developed gels using various kinetic models was checked and were found to be following non-fickian diffusion mechanism and first-order kinetics. In vivo studies carried on Freund’s adjuvant induced monoarthritis in male w istar rats; results showed a significant reduction in the inflammation at the test site. The gels were biocompatible since no inflammation was observed in the synovial membrane. MTX in situ gels could be proposed as an effective delivery system management of RA in near future.
Highlights
Rheumatoid arthritis (RA) an autoimmune disease due to which there is loss of joint space leading to its dysfunctionality and deformity
The results demonstrated that MTX was uniformly distributed and the in situ gels were sterile and syringeable
MTX was supplied by Strides Arcolabs Limited, Bengaluru; Pluronic F-127 (Sigma Aldrich, USA), xanthan gum (CP Kelco, USA), Benzalkonium Chloride (Reachem Labs, Chennai), Potassium Dihydrogen Phosphate (Merck Specialities Ltd, Mumbai), Hydrochloric Acid (Reachem Lab, Chennai), Sodium Hydroxide (Merck Specialities Ltd, Mumbai), LA395 Dialysis Membrane 135 (Hi-media labs, Mumbai) were procured and used without any further processing
Summary
Rheumatoid arthritis (RA) an autoimmune disease due to which there is loss of joint space leading to its dysfunctionality and deformity. It is progressive in nature and causes irreversible damage to the synovial-lined joints. It has widespread presence of about 1% in adult population. The prevalence of RA in common population has been estimated to be 0.8%, especially begins with fourth and fifth decades of life with a two- to three-fold greater frequency in women than in men (rheumatology.org; Rudan et al, 2015).
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
